Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseLife at Premier By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Consulting Orphan Drug Designation: When Is It Appropriate, and How Does It Apply to Orphan Subsets? By Vanessa Atayde September 5, 2023 Clinical ResearchPhase 1 - Phase 4 The Multi-Faceted World of Clinical Trial Matching in Precision Oncology Studies By Premier Research September 1, 2023 Clinical ResearchPhase 1 - Phase 4 Where Biomarkers and Gene Therapy Trials Intersect: Benefits Abound By Kenneth Ndugga-Kabuye September 1, 2023 Clinical ResearchPhase 1 - Phase 4 A Different Pace: Meeting the Demands of Liquid Biopsy Development for Early Cancer Detection By Charles Chrisawn July 18, 2023 Clinical ResearchPhase 1 - Phase 4 It’s Better for Everyone: The Promise of Liquid Biopsy as a Cancer Screening Tool By Charles Chrisawn July 17, 2023 Clinical ResearchPhase 1 - Phase 4 Food for Thought: The Power of Decentralized Clinical Trials in Accelerating Infant Formula Studies By Betsy Reid June 20, 2023 Previous 1 …5 6 7 8 9 … 57 Next × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today